Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose combination of berberine hydrochloride and mesalazine. Berberine hydrochloride is an isoquinoline alkaloid with broad-spectrum antimicrobial, anti-inflammatory, and antidiarrheal properties, commonly used for gastrointestinal infections such as gastroenteritis and diarrhea. Mesalazine (also known as mesalamine or 5-aminosalicylic acid) is an aminosalicylate anti-inflammatory drug primarily used to treat inflammatory bowel diseases like ulcerative colitis and Crohn's disease. The combination has been studied for the treatment of distal ulcerative colitis, where it has shown enhanced efficacy in reducing inflammation markers compared to monotherapy with either agent[1][2][4][7]. Berberine acts by inhibiting bacterial DNA synthesis and modulating inflammatory pathways, while mesalazine inhibits cyclooxygenase and lipoxygenase pathways in the colon mucosa to reduce prostaglandin production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on berberine hydrochloride + mesalazine.